E37: Errik Anderson on Co-Founding 20 Biotech Startups Cumulatively Worth $10B+

Errik Anderson sits down with David Weisburd to discuss Pro-noia, the potential of the biotech industry, and the 82VS Seed Fund investment approach. They discuss practicing Pro-noia, the value of building a portfolio of relationships, and the idea of a forever company. (0:00) Introduction to pronoia and its importance (0:20) Background on Errik Anderson's career and co-founding companies (0:49) Adamab's business model and biotech's impact on the world (3:28) The role of AI in biotech and the concept of a startup factory (7:47) Challenges in biotech and applying tech investment models (12:36) Alloy Therapeutics' business model and biotech economic challenges (18:15) Reducing costs and differences between digital and biotech startups (20:22) Experimentation before funding and fund size strategies (22:45) The importance of collaboration in the investment world (25:33) Collaborative approach: Benefits, challenges, and early-stage investments (32:00) Balancing small bets with long-term relationships and mental diet (37:33) Creating wealth, family values, and children's focus on strengths (45:49) Mentorship styles and finding satisfaction in work (49:26) Strategic finance, partnerships, and personal growth (53:54) Future plans for Alloy, collaborative investments, and fund management (59:10) Alloy's commitment and the concept of generosity in business (1:00:42) Closing remarks and gratitude (1:00:56) Sponsor: Carrier Labs and newsletter announcement